Now showing items 1-3 of 3

    • Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. 

      George, A; Riddell, D; Seal, S; Talukdar, S; Mahamdallie, S; Ruark, E; Cloke, V; Slade, I; Kemp, Z; Gore, M; Strydom, A; Banerjee, S; Hanson, H; Rahman, N (2016-07-13)
      Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing ...
    • The integration of BRCA testing into oncology clinics. 

      Percival, N; George, A; Gyertson, J; Hamill, M; Fernandes, A; Davies, E; Rahman, N; Banerjee, S (2016-06)
      <h4>Purpose</h4>The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA ...
    • Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. 

      Smrke, A; Younger, E; Wilson, R; Husson, O; Farag, S; Merry, E; Macklin-Doherty, A; Cojocaru, E; Arthur, A; Benson, C; Miah, AB; Zaidi, S; Gennatas, S; Jones, RL (2020-07)
      <h4>Purpose</h4>Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, ...